Document is current
Any future updates will be listed below
-
Authors
Okoro, Clementina E.
Jamro, Erica L.
Orji, Anthony I.
Van Horn, Linda V.
Alfa, Vanessa
Obagha, Chijioke
Ojo, Adedayo E.
Ekechi, Henry
Okoli, Rosemary
Alex-Okoh, Morenike
Chukwuma, Anyaike
Maduforo, Aloysius N.
Adurosakin, Felix
Odoh, Deborah
Toma, Malau Mangai
Sopekan, Alayo
George, Aniekeme
Fagbamigbe, Adeniyi F.
Uwakmfon, Uduak
John, Doris
Afolabi, Rotimi F.
Iyer, Guhan
Hirschhorn, Lisa R.
Neal, Bruce
Jones, Alexandra
Trieu, Kathy
Marklund, Matti
Ilias, Maliha
Tonwe, Veronica
Peasley, Julia M. Lorenzana
Harnack, Lisa J.
Huffman, Mark D.
Ojji, Dike B.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (UH3HL152381)
- License Information
-
More Information
Article History
Received: 28 March 2025
Accepted: 9 October 2025
First Online: 17 November 2025
Declarations
:
: MDH has received travel support from the World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. The other authors have no relationships with industry to disclose.
: All participants provided written informed consent.
: The institutional review boards at University of Abuja, Northwestern University, and University of New South Wales approved the study procedures in accordance with the Declaration of Helsinki.
: The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.
